Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026GlobeNewsWire • 10/26/26
Iovance Presents New Data at ESMO 2026 Demonstrating Deep, Durable Responses with Lifileucel TIL Cell Therapy Plus Pembrolizumab in Frontline Advanced MelanomaGlobeNewsWire • 10/23/26
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026GlobeNewsWire • 10/19/26
Undercovered Dozen: Hess Midstream, Iovance Biotherapeutics, Netlist, And MoreSeeking Alpha • 10/19/26
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewsWire • 10/16/26
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerGlobeNewsWire • 10/01/26
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?Benzinga • 09/30/26
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?Zacks Investment Research • 09/30/26
Iovance Biotherapeutics' Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock SoarsBenzinga • 09/29/26
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 MillionGlobeNewsWire • 09/29/26
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and PrecigenZacks Investment Research • 08/27/26
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to BuyZacks Investment Research • 08/20/26
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor UpdatesSeeking Alpha • 08/20/26
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?The Motley Fool • 08/10/26